Epiq Partners, LLC Fate Therapeutics Inc Transaction History

Epiq Partners, LLC

  • $140 Million
  • Q1 2024

A detailed history of Epiq Partners, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Epiq Partners, LLC holds 10,071 shares of FATE stock, worth $31,925. This represents 0.05% of its overall portfolio holdings.

Number of Shares
10,071
Previous 10,071 -0.0%
Holding current value
$31,925
Previous $37,000 97.3%
% of portfolio
0.05%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 11, 2024
BUY
$1.65 - $3.94 $16,617 - $39,679
10,071 New
10,071 $37,000
Q2 2023

Jul 12, 2023
BUY
$4.76 - $6.59 $47,937 - $66,367
10,071 New
10,071 $47,000
Q4 2022

Jan 06, 2023
SELL
$9.86 - $23.83 $12,275 - $29,668
-1,245 Reduced 1.71%
71,521 $0
Q3 2022

Oct 14, 2022
BUY
$21.04 - $36.06 $83,591 - $143,266
3,973 Added 5.78%
72,766 $1.63 Million
Q2 2022

Jul 07, 2022
BUY
$17.78 - $42.39 $195,313 - $465,654
10,985 Added 19.0%
68,793 $1.71 Million
Q1 2022

Apr 27, 2022
BUY
$29.67 - $60.28 $273,112 - $554,877
9,205 Added 18.94%
57,808 $2.24 Million
Q4 2021

Jan 25, 2022
SELL
$47.84 - $64.34 $11,242 - $15,119
-235 Reduced 0.48%
48,603 $2.84 Million
Q3 2021

Oct 19, 2021
SELL
$59.27 - $95.73 $50,201 - $81,083
-847 Reduced 1.7%
48,838 $2.9 Million
Q2 2021

Aug 02, 2021
BUY
$67.25 - $92.52 $197,042 - $271,083
2,930 Added 6.27%
49,685 $4.31 Million
Q1 2021

Apr 16, 2021
BUY
$72.16 - $117.4 $237,189 - $385,893
3,287 Added 7.56%
46,755 $3.86 Million
Q4 2020

Jan 11, 2021
BUY
$38.09 - $100.95 $198,258 - $525,444
5,205 Added 13.6%
43,468 $3.95 Million
Q3 2020

Oct 22, 2020
BUY
$30.41 - $40.5 $1.16 Million - $1.55 Million
38,263 New
38,263 $1.7 Million

Others Institutions Holding FATE

# of Institutions
178
Shares Held
124M
Call Options Held
222K
Put Options Held
48.6K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $307M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Epiq Partners, LLC Portfolio

Follow Epiq Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Epiq Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Epiq Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email